» Articles » PMID: 15010370

NTAL Phosphorylation is a Pivotal Link Between the Signaling Cascades Leading to Human Mast Cell Degranulation Following Kit Activation and Fc Epsilon RI Aggregation

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 2004 Mar 11
PMID 15010370
Citations 54
Authors
Affiliations
Soon will be listed here.
Abstract

Aggregation of high-affinity receptors for immunoglobulin E (Fc epsilon RI) on the surface of mast cells results in degranulation, a response that is potentiated by binding of stem cell factor (SCF) to its receptor Kit. We observed that one of the major initial signaling events associated with Fc epsilon RI-mediated activation of human mast cells (HuMCs) is the rapid tyrosine phosphorylation of a protein of 25 to 30 kDa. The phosphorylation of this protein was also observed in response to SCF. This protein was identified as non-T-cell activation linker (NTAL), an adaptor molecule similar to linker for activated T cells (LAT). Unlike the Fc epsilon RI response, SCF induced NTAL phosphorylation in the absence of detectable LAT phosphorylation. When SCF and antigen were added concurrently, there was a marked synergistic effect on NTAL phosphorylation, however, SCF did not enhance the phosphorylation of LAT induced by Fc epsilon RI aggregation. Fc epsilon RI- and SCF-mediated NTAL phosphorylation appear to be differentially regulated by Src kinases and/or Kit kinase, respectively. Diminution of NTAL expression by silencing RNA oligonucleotides in HuMCs resulted in a reduction of both Kit- and Fc epsilon RI-mediated degranulation. NTAL, thus, appears to be an important link between the signaling pathways that are initiated by these receptors, culminating in mast cell degranulation.

Citing Articles

Mast Cell-Targeting Therapies in Mast Cell Activation Syndromes.

Sabato V, Beyens M, Toscano A, Van Gasse A, Ebo D Curr Allergy Asthma Rep. 2024; 24(2):63-71.

PMID: 38217824 DOI: 10.1007/s11882-023-01123-9.


Review and Updates on Systemic Mastocytosis and Related Entities.

Li J, Ryder C, Zhang H, Cockey S, Hyjek E, Moscinski L Cancers (Basel). 2023; 15(23).

PMID: 38067330 PMC: 10705510. DOI: 10.3390/cancers15235626.


Degranulation of Mast Cells as a Target for Drug Development.

Yang B, Kim A, Lee D, An S, Shim Y, Jang M Cells. 2023; 12(11).

PMID: 37296626 PMC: 10253146. DOI: 10.3390/cells12111506.


Research Advances in Mast Cell Biology and Their Translation Into Novel Therapies for Anaphylaxis.

Dispenza M, Metcalfe D, Olivera A J Allergy Clin Immunol Pract. 2023; 11(7):2032-2042.

PMID: 36958519 PMC: 10330051. DOI: 10.1016/j.jaip.2023.03.015.


Drug delivery targets and strategies to address mast cell diseases.

Rische C, Thames A, Krier-Burris R, OSullivan J, Bochner B, Scott E Expert Opin Drug Deliv. 2023; 20(2):205-222.

PMID: 36629456 PMC: 9928520. DOI: 10.1080/17425247.2023.2166926.